Eftilagimod alpha
Eftilagimod alpha (INN; development code IMP321 or efti) is a large-molecule cancer drug being developed by the clinical-stage biotechnology company Immutep. Efti is a soluble version of the immune checkpoint molecule LAG-3. It is an APC Activator used to increase an immune response to tumors, and is administered by subcutaneous injection. Efti has three intended clinical settings:
- as adjuvant to cancer vaccines (in a low, effective dose of ~250 µg)
- as first-line 'chemo-immunotherapy,' that is, combined with standard chemotherapy (e.g. paclitaxel)
- in combination immunotherapy with PD-1 treatments (e.g. pembrolizumab)
| Clinical data | |
|---|---|
| Trade names | ImmuFact |
| Other names | Efti, IMP321 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
Eftilagimod alpha is in Phase II clinical testing. Currently, the main indications for the drug are metastatic breast cancer, non-small cell lung cancer (NSCLC), and head and neck squamous cell carcinoma (HNSCC).
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.